Terbutaline Sulfate
A to Z Drug Facts
Terbutaline Sulfate |
(ter-BYOO-tuh-leen SULL-fate) |
Brethaire, Brethine, Bricanyl |
Class: Bronchodilator/Sympathomimetic |
Action Produces bronchodilation by relaxing bronchial smooth muscle through beta2-receptor stimulation.
Indications Treatment of reversible bronchospasm associated with asthma, bronchitis and emphysema. unlabeled use (S): Inhibits premature labor.
Contraindications Cardiac arrhythmias associated with tachycardia.
ADULTS & CHILDREN ³ 12 YR: Inhalation 2 inhalations (separated by 60 sec interval) q 46 hr. Do not repeat more than q 4 hr. ADULTS & CHILDREN ³ 15 YR: PO 2.55 mg at 6 hr intervals, 3 times per day during waking hours. Do not exceed 15 mg in 24 hr. CHILDREN 1215 YR: PO 2.5 mg tid. Do not exceed 7.5 mg in 24 hr. SC 0.25 mg given in lateral deltoid area. May repeat in 1530 min. Do not exceed 0.5 mg in 4 hr.
Premature Labor Inhibition
ADULTS: IV 1080 mcg/min for 4 hr has shown some success. Maintenance: PO 2.5 mg q 46 hr.
Beta-blockers: Block bronchodilator effect of terbutaline. MAO inhibitors: Hypertension may occur. Tricyclic antidepressants: Cardiovascular effects of terbutaline may be enhanced.
Lab Test Interferences None well documented.
CV: Palpitations; tachycardia; chest discomfort or pain; arrhythmias; blood pressure changes/hypertension. CNS: Stimulation; tremor; dizziness; nervousness; drowsiness; headache; weakness. GI: Nausea; vomiting; GI distress. HEPA: Elevated liver enzymes. META: Hypokalemia (with high doses). RESP: Dyspnea. OTHER: Flushing; sweating; muscle cramps; hypersensitivity vasculitis; ECG changes (eg, sinus pause, atrial premature beats, AV block, ventricular premature beats, ST-T-wave depression, T-wave inversion, sinus bradycardia, atrial escape beat with aberrant conduction); increased heart rate; muscle cramps; central stimulations; pain at injection site; elevations in liver enzymes; seizures; hypersensitivity vasculitis.
Pregnancy: Category B. Lactation: Excreted in breast milk. Labor and delivery: May inhibit uterine contractions and delay preterm labor. Children: Safety and efficacy in children < 12 years not established. Elderly: Lower doses may be required. Cardiovascular effects: Toxic symptoms in patients with cardiovascular disorders may occur. CNS effects: CNS stimulation may occur; use cautiously in patients with history of seizures or hyperthyroidism. Carcinogenesis: A significant increase in the incidence of leiomyomas of the mesovarium and ovarian cysts has been demonstrated. Diabetes: Dosage adjustment of insulin or oral hypoglycemic agent may be required. Excessive use: Paradoxical bronchospasm and cardiac arrest have been associated with excessive inhalant use. Hypersensitivity: Hypersensitivity (allergic) reactions can occur after administration. Hypokalemia: Decreases in potassium levels have occurred. Tolerance: If previously effective dose fails to provide relief, therapy may need to be reassessed.
PATIENT CARE CONSIDERATIONS |
|
|
Books@Ovid
Copyright © 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts